CEFALY Receives Recognition as Top Neuromodulation Device for Veterans' Migraine Treatment

CEFALY: Leading the Way in Neuromodulation for Veterans' Migraines

In a significant announcement from CEFALY Technology, the company has revealed that its neuromodulation device, CEFALY Connected, has reached a milestone as the most frequently prescribed device for migraine treatment among veterans by the Veterans Health Administration (VHA). In 2024, a staggering 21,593 neuromodulation devices were dispensed for migraine relief within the VHA, with CEFALY being prescribed in over half of these cases, precisely 53% or 11,472 devices.

The Growing Burden of Migraines among Veterans

Migraine is not just a common headache; it is a complex neurological condition that can significantly impair daily functioning. Research indicates that U.S. veterans suffer from migraines at higher rates compared to the general population. A study covering more than 490,000 veterans showed that 8.2% of men and a troubling 30.1% of women reported having migraines, compared to 6% and 17% in the general populace.

These statistics reflect a grave health challenge, as veterans with migraines often grapple with coexisting conditions such as post-traumatic stress disorder (PTSD), depression, anxiety, and traumatic brain injuries. Graduating from standard migraine management protocols, CEFALY has now become a critical component in the broader landscape of veterans' healthcare, particularly addressing the complexity of migraine treatment amid these comorbidities.

Importance of Non-Pharmacologic Treatments

Dr. Michael A. L. Johnson, a medical advisor for CEFALY, emphasized the significance of non-drug treatment methods for veterans confronting multiple health issues. Prescribing conventional medications can lead to complications due to adverse effects or drug interactions, particularly in individuals with a complicated medical history. In this context, CEFALY offers a non-invasive neuromodulation solution that proves to be both effective and safe for migraine management.

The device utilizes mild stimulation to target the trigeminal nerve, the primary pathway implicated in migraine pain. Furthermore, it interfaces with the CeCe Migraine Management app, allowing users to monitor their treatment sessions and manage their migraine journey effectively. This level of engagement and self-management significantly enhances the quality of life for veterans.

Supporting Veterans’ Well-Being

Andy Page, the CEO of CEFALY Technology, expressed a heartfelt commitment to veterans, stating, “No veteran should have to live with the disabling symptoms of migraine.” This commitment aligns with CEFALY’s mission to alleviate the suffering and improve the overall well-being of veterans who face the daily challenges posed by migraines.

As a company rooted in innovation, CEFALY Technology, based in Belgium with U.S. operations in Darien, Connecticut, places a strong emphasis on enabling individuals with migraines to take control of their treatment options, leading to improved health outcomes and enhanced quality of life. The FDA-cleared, over-the-counter wearable device is not only a breakthrough in medical technology but a beacon of hope for many.

In conclusion, the recognition of CEFALY Connected as the top neuromodulation device in the VHA underscores the critical role that innovative medical technologies play in addressing the healthcare needs of veterans—particularly in managing migraine pain. By enabling veterans to reclaim their lives from the burdens of migraines, CEFALY champions a future where effective treatment is accessible, comprehensive, and holistic.